Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2015

Open Access 01-12-2015 | Commentary

Why are there deadly drugs?

Author: Joel Lexchin

Published in: BMC Medicine | Issue 1/2015

Login to get access

Abstract

Some drugs eventually have to be removed from the market because of a negative benefit-to-harm ratio, including an excess of mortality. Drug safety is the result of multiple factors, commencing with how clinical trials are designed, the information generated by and/or hidden through these trials, trial analysis by drug regulatory authorities (DRAs) and the amount of information that DRAs choose to release, the amount of published information regarding drug safety, the effectiveness of postmarket surveillance systems in recognizing and reporting adverse drug reactions, and the structure of DRAs such as the United States Food and Drug Administration and its equivalent in other countries. This commentary will look at each of these issues in order to highlight the problems in the current approach to drug safety and finally indicate how some of these deficiencies should be addressed.
Please see related article: http://​dx.​doi.​org/​10.​1186/​s12916-014-0262-7
Literature
1.
Onakpoya I, Heneghan C, Aronson J. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Medicine 2015.
2.
Friedman M, Woodcock J, Lumpkin M, Shuren J, Hass A, Thompson L. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA. 1999;281:1728–34.CrossRefPubMed
3.
World Health Organization. The world medicines situation report. Geneva: WHO; 2004.
4.
Pal S, Dodoo A, Mantel A, Olsson S. The world medicines situation 2011: pharmacovigilance and safety of medicines. Geneva: WHO; 2011.
5.
Kamal-Yanni M, Saunders P. Urgent need for WHO’s reform to prioritise core functions. Lancet. 2012;379:1878.
6.
Lurie P, Wofle SM. Misleading data analyses in salmeterol (SMART) study. Lancet. 2005;366:1261–2.CrossRefPubMed
7.
Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. JAMA. 2008;299:1813–7.CrossRefPubMed
8.
Woloshin S, Schwartz L. Bringing the FDA’s information to market. Arch Intern Med. 2009;169:1985–7.CrossRefPubMed
9.
Habibi R, Lexchin J. Quality and quantity of information in summary basis of decision documents issued by health Canada. PLoS One. 2014;9:e92038.
10.
Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ. 2011;342:d2291.
11.
Carpenter D, Zucker E, Avorn J. Drug-review deadlines and safety problems. New Engl J Med. 2008;358:1354–61.CrossRefPubMed
12.
Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172:1680–1.CrossRefPubMed
13.
Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med. 2009;169:1756–61.CrossRefPubMed
14.
Breau R, Gaboury I, Scales C, Fesperman S, Watterson J, Dahm P. Reporting of harm in randomized controlled trials published in the urological literature. J Urol. 2010;183:1693–7.CrossRefPubMed
15.
Hazell L, Shakir S. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.CrossRefPubMed
16.
Mittmann N, Knowles S, Gomez M, Fish J, Cartotto R, Shear N. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004;27:477–87.CrossRefPubMed
17.
Moore T, Cohen M, Furberg C. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007;167:1752–9.CrossRefPubMed
18.
Mundy A. Dispensing with the truth: the victims, the drug companies, and the dramatic story behind the battle over fen-phen. New York: St. Martin’s Press; 2001.
19.
Wiktorowicz M, Lexchin J, Moscou K, Silversides A, Eggertson L. Keeping an eye on prescription drugs, keeping Canadians safe: active monitoring systems for drug safety and effectiveness in Canada and internationally. Toronto: Health Council of Canada; 2010.
20.
Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton University Press: Princeton; 2010.
Metadata
Title
Why are there deadly drugs?
Author
Joel Lexchin
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2015
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-015-0270-2

Other articles of this Issue 1/2015

BMC Medicine 1/2015 Go to the issue

Tutorial

A guide to performing a peer review of randomised controlled trials

Research article

Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study

Research article

Sex differences in medico-legal action against doctors: a systematic review and meta-analysis

Research article

Maternal and child health nurse screening and care for mothers experiencing domestic violence (MOVE): a cluster randomised trial

Research article

Western diet is associated with a smaller hippocampus: a longitudinal investigation

Minireview

Advances in the treatment of newly diagnosed glioblastoma